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Tamoxifen (TAM) is the mainline drug treatment for breast cancer, despite its side effects and 
the development of resistance. As an alternative approach, in the present study a novel 
combination therapy was established through combining TAM with nordamnacanthal 
(NDAM) in order to investigate the additive effect of these drugs in MCF-7 human breast 
cancer cells. A significant dose-dependent reduction in cell viability and an increase in 
apoptosis were observed in the MCF-7 cells cotreated with TAM and NDAM compared with 
the untreated control cells or the cells treated with TAM and NDAM alone (P<0.05). The 
cytotoxic influence of the combination of TAM and NDAM was found to be two-fold that of 
the individual agents. Annexin V/propidium iodide double-staining revealed the typical nuclear 
features of apoptosis. Furthermore, an increase in the proportion of apoptotic, Annexin V-
positive cells was observed with the combination therapy. Moreover, this apoptotic induction 
was associated with a collapse of the mitochondrial membrane potential and the generation of 
reactive oxygen species. To the best of our knowledge, the findings of the present study are the 
first to suggest that combining TAM with NDAM may be a potential combination therapy for 
the treatment of breast cancer and may have the potential to minimize or eliminate the side 
effects associated with high doses of TAM. 
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